

Brilinta - (90mg; Tablet, Oral)

| | | | |
|------------------------------|---|-----------------------------|---------------------|
| Generic Name | Ticagrelor | Innovator | Astrazeneca |
| Dosage | 90mg; Tablet, Oral | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | More Than 5 | Known Para IV Filers | More Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | More Than 5 |
| Final Approvals | Less Than 5 | Generic Launches | None |
| Indication | Indicated to reduce the rate of thrombotic cardiovascular (CV) events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST-elevation myocardial infarction, or ST-elevation myocardial infarction) | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Brilinta - (60mg; Tablet, Oral)

| | | | |
|------------------------------|---|-----------------------------|---------------------|
| Generic Name | Ticagrelor | Innovator | Astrazeneca |
| Dosage | 60mg; Tablet, Oral | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | More Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | More Than 5 |
| Final Approvals | Less Than 5 | Generic Launches | None |
| Indication | Indicated to reduce the rate of thrombotic cardiovascular (CV) events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST-elevation myocardial infarction, or ST-elevation myocardial infarction) | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.